Search clinical trials for: JS005 (recombinant humanized monoclonal antibody against IL-17A)

Total 262 results

Shanghai Junshi Bioscience Co., Ltd.

Completed

Safety, Tolerance, Efficacy and Pharmacokinetics of JS005 Multiple Dosing

Moderate to Severe Psoriasis

China
Shanghai Junshi Bioscience Co., Ltd.
Sponsor GmbH

Recruiting

Evaluate the Preliminary Efficacy, Safety, and PK of Subcutaneous JS005 in Chinese Adult Patients With Active AS

Active Ankylosing Spondylitis

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

A Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adults With Moderate to Severe Chronic Plaque Psoriasis

Moderate to Severe Chronic Plaque Psoriasis

China
Shanghai Junshi Bioscience Co., Ltd.
Sponsor GmbH

Recruiting

Evaluate the Preliminary Efficacy, Safety, and PK of Subcutaneous JS005 in Chinese Adult Patients With Active Nr-axSpA

Non-radiographic Axial Spondyloarthritis

China
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Phase I Study of Comparing Single Dose JS005 (Recombinant Humanized Monoclonal Antibody Against IL-17A) With Placebo in Tolerability, Safety, Immunogenicity and Pharmacokinetic in Healthy Volunteers

Tolerability, Safety, Immunogenicity and Pharmacokinetic of JS005

China
Shanghai Junshi Bioscience Co., Ltd.
Sponsor GmbH

Recruiting

A Clinical Study of JS005 in Patients With Ankylosing Spondylitis

Ankylosing Spondylitis

China
Bio-Thera Solutions

Active, not recruiting

Assessment on Efficacy and Safety of BAT2306 and Cosentyx® in Plaque Psoriasis Patients

Plaque Psoriasis

China
Shanghai Huaota Biopharmaceutical Co., Ltd.

Recruiting

Efficacy and Safety of HB0034 in Patients With Generalized Pustular Psoriasis (GPP)

Generalized Pustular Psoriasis (GPP)

China
Biocad

Completed

First-in-human Study to Evaluate Safety, Tolerability and Pharmacokinetics of Various Doses of BCD-085 in Healthy Subjects

Healthy
Bio-Thera Solutions

Terminated

Assessment of Safety and Preliminary Efficacy With BAT6021 in Solid Tumor Patients in China

Solid Tumor

China
Shanghai Huaota Biopharmaceutical Co., Ltd.

Completed

HB0034 in Patients With Generalized Pustular Psoriasis (GPP)

Generalized Pustular Psoriasis

China
Sun Yat-sen University
Shanghai Junshi Bioscience Co., Ltd.

Unknown

JS001 Combined With Regorafenib in Patients With Advanced Colorectal Cancer

Colorectal Cancer

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

A Single Dose Escalation Study of PCSK9 Inhibitor (JS002) in Health Subjects

Hypercholesterolemia

China
Biocad

Completed

Dose Escalation Study of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of BCD-132 in Patients With Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis

Russian Federation
Sinocelltech Ltd.

Not yet recruiting

Efficacy and Safety of SCT650C in Participants With Axial Spondyloarthritis

Axial Spondyloarthritis

Turkey
Sinocelltech Ltd.

Not yet recruiting

Evaluate the Safety and Tolerability of SCT650C in Healthy Volunteers

Autoimmune Disease

Australia
Shanghai Junshi Bioscience Co., Ltd.

Completed

The Safety and Efficacy of Multiple-dose of JS004 in Subject With HNC

Nasopharyngeal Carcinoma | Head and Neck Squamous Cell Carcinom

China
Shanghai Huaota Biopharmaceutical Co., Ltd.

Completed

A Study to Evaluate Multi-dose of HB0034 in Healthy Adult Participants

Healthy

New Zealand
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Active, not recruiting

A Phase 2 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque Psoriasis

Psoriasis

China
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Recruiting

A Phase Ib/II Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout

Acute Gout

China
Shanghai Henlius Biotech

Recruiting

The Efficacy and Safety of HLX07 in Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC)

Cutaneous Squamous Cell Carcinoma

China
Shanghai Junshi Bioscience Co., Ltd.
Iqvia Pty Ltd; TopAlliance Biosciences, Inc.

Active, not recruiting

Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies

Advanced Malignancies

United States
Shanghai Henlius Biotech

Not yet recruiting

HLX07(Anti-EGFR mAb) in Patients With Advanced or Metastatic Solid Tumors

Solid Tumor

China
Beijing VDJBio Co., LTD.

Recruiting

A Study of Anti-IL-6R mAb Injection in Patients With iMCD

Idiopathic Multicentric Castleman's Disease

China
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Safety, Tolerability and Pharmacokinetics of a Recombinant Humanized mAb Specific to B-and T-Lymphocyte Attenuator (BTLA) for Injection in Subjects With Advanced Malignancies

Advanced Solid Tumor

China
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Recruiting

A Study of SSGJ-613 in Gout Subjects Initiating Urate-Lowering Treatment.

Gout Arthritis

China
Genor Biopharma Co., Ltd.

Recruiting

Clinical Trial in Chinese Patients of Elapsed/Metastatic/Unresectable Alveolar Soft Part Sarcoma(GB226)

Alveolar Soft Part Sarcoma

China
Shanghai Henlius Biotech

Recruiting

A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric Cancer

Gastric Cancer

China
CARsgen Therapeutics Co., Ltd.
Shanghai East Hospital

Completed

Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors

Gastric Cancer | Pancreatic Adenocarcinoma | Solid Tumor

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

A Phase I Clinical Study of JS004 in Subjects With Recurrent/Refractory Malignant Lymphoma of China

Recurrent/Refractory Malignant Lymphoma

China
Genor Biopharma Co., Ltd.

Recruiting

Clinical Trial in Chinese Patients of Relapsed and Refractory Peripheral T Cell Lymphoma (GB226)

Peripheral T Cell Lymphoma

China
United BioPharma

Not yet recruiting

Evaluating the Safety and Tolerability and Determining the PK and PD of Single Dose UB-221 in Chronic Spontaneous Urticaria

Chronic Idiopathic Urticaria
Biocad

Completed

First-in-human Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Various Doses of BCD-121 in Healthy Subjects

Healthy
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody Toripalimab for Patients With Advanced Solid Tumors

Melanoma | Urological Cancer

China
Huabo Biopharm Co., Ltd.

Recruiting

A Study of Injection HB0025 in Patients With Advanced Solid Tumors

Tumor, Subjects

United States, China
Shanghai Henlius Biotech
Hengenix Biotech Inc; Sanyou Biopharmaceuticals(Shanghai)Co., Ltd; Shanghai ZJ...

Withdrawn

Evaluate Safety and Pharmacokinetics of HLX70 in Healthy Adult Volunteers

COVID-19
Beijing Mabworks Biotech Co., Ltd.

Recruiting

A Clinical Study of MIL95 in Advanced Malignancies.

Advanced Malignancies

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JS004 in Advanced Solid Tumors

Melanoma | Urothelial Carcinoma | Renal Carcinoma

China
United BioPharma

Recruiting

A Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Efficacy of UB-221 IV Infusion as an add-on Therapy in Patients With Chronic Spontaneous Urticaria

Chronic Spontaneous Urticaria

Taiwan
Peking University
Shanghai Junshi Bioscience Co., Ltd.

Completed

Study of JS001 in Patients With Advanced Neuroendocrine Tumors

Neuroendocrine Tumors

China
Bio-Thera Solutions

Terminated

Assessment of Safety and Preliminary Efficacy With BAT6021 in Solid Tumor Patients

Advanced Solid Tumor

Australia
Beijing Mabworks Biotech Co., Ltd.

Recruiting

A Clinical Study of MIL93 in Solid Tumors.

Advanced Malignancies

China
Beijing Mabworks Biotech Co., Ltd.

Completed

A Study of MIL62 in Treatment of CD20 Positive B-cell Lymphomas

CD20-positive B Cell Non-Hodgkin Lymphoma

China
Tracon Pharmaceuticals Inc.

Completed

Phase 1, Open-label, Dose Escalation Study of TRC093, in Patients With Locally Advanced or Metastatic Solid Tumors

Cancer | Neoplasm Metastasis

United States
Bio-Thera Solutions

Not yet recruiting

Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8008 for Injection

Advanced Solid Tumors
Beijing Mabworks Biotech Co., Ltd.

Recruiting

Treatment of Advanced and Metastatic Solid Tumors With MIL97

Advanced or Metastatic Solid Tumor

China
Beijing InnoCare Pharma Tech Co., Ltd.

Active, not recruiting

A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma

B-cell Lymphoma Refractory | B-cell Lymphoma Recurrent

China
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Tolerability and Pharmacokinetics of Toripalimab in Combination With Axitinib in Patients With Kidney Cancer and Melanoma

Advanced Melanoma | Kidney Cancer Stage Iv

China
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Safety and Efficacy of Toripalimab for Patients With Locally Advanced or Metastatic Bladder Urothelial Carcinoma

Bladder Urothelial Carcinoma

China
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Patients With Locally Advanced or Metastatic Melanoma

Metastatic Melanoma | Advanced Melanoma

China

3

Subscribe